Cargando…

mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles

In the quest for a formidable weapon against the SARS-CoV-2 pandemic, mRNA therapeutics have stolen the spotlight. mRNA vaccines are a prime example of the benefits of mRNA approaches towards a broad array of clinical entities and druggable targets. Amongst these benefits is the rapid cycle “from de...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouranidis, Andreas, Vavilis, Theofanis, Mandala, Evdokia, Davidopoulou, Christina, Stamoula, Eleni, Markopoulou, Catherine K., Karagianni, Anna, Kachrimanis, Kyriakos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773365/
https://www.ncbi.nlm.nih.gov/pubmed/35052730
http://dx.doi.org/10.3390/biomedicines10010050
_version_ 1784636066808987648
author Ouranidis, Andreas
Vavilis, Theofanis
Mandala, Evdokia
Davidopoulou, Christina
Stamoula, Eleni
Markopoulou, Catherine K.
Karagianni, Anna
Kachrimanis, Kyriakos
author_facet Ouranidis, Andreas
Vavilis, Theofanis
Mandala, Evdokia
Davidopoulou, Christina
Stamoula, Eleni
Markopoulou, Catherine K.
Karagianni, Anna
Kachrimanis, Kyriakos
author_sort Ouranidis, Andreas
collection PubMed
description In the quest for a formidable weapon against the SARS-CoV-2 pandemic, mRNA therapeutics have stolen the spotlight. mRNA vaccines are a prime example of the benefits of mRNA approaches towards a broad array of clinical entities and druggable targets. Amongst these benefits is the rapid cycle “from design to production” of an mRNA product compared to their peptide counterparts, the mutability of the production line should another target be chosen, the side-stepping of safety issues posed by DNA therapeutics being permanently integrated into the transfected cell’s genome and the controlled precision over the translated peptides. Furthermore, mRNA applications are versatile: apart from vaccines it can be used as a replacement therapy, even to create chimeric antigen receptor T-cells or reprogram somatic cells. Still, the sudden global demand for mRNA has highlighted the shortcomings in its industrial production as well as its formulation, efficacy and applicability. Continuous, smart mRNA manufacturing 4.0 technologies have been recently proposed to address such challenges. In this work, we examine the lab and upscaled production of mRNA therapeutics, the mRNA modifications proposed that increase its efficacy and lower its immunogenicity, the vectors available for delivery and the stability considerations concerning long-term storage.
format Online
Article
Text
id pubmed-8773365
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87733652022-01-21 mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles Ouranidis, Andreas Vavilis, Theofanis Mandala, Evdokia Davidopoulou, Christina Stamoula, Eleni Markopoulou, Catherine K. Karagianni, Anna Kachrimanis, Kyriakos Biomedicines Review In the quest for a formidable weapon against the SARS-CoV-2 pandemic, mRNA therapeutics have stolen the spotlight. mRNA vaccines are a prime example of the benefits of mRNA approaches towards a broad array of clinical entities and druggable targets. Amongst these benefits is the rapid cycle “from design to production” of an mRNA product compared to their peptide counterparts, the mutability of the production line should another target be chosen, the side-stepping of safety issues posed by DNA therapeutics being permanently integrated into the transfected cell’s genome and the controlled precision over the translated peptides. Furthermore, mRNA applications are versatile: apart from vaccines it can be used as a replacement therapy, even to create chimeric antigen receptor T-cells or reprogram somatic cells. Still, the sudden global demand for mRNA has highlighted the shortcomings in its industrial production as well as its formulation, efficacy and applicability. Continuous, smart mRNA manufacturing 4.0 technologies have been recently proposed to address such challenges. In this work, we examine the lab and upscaled production of mRNA therapeutics, the mRNA modifications proposed that increase its efficacy and lower its immunogenicity, the vectors available for delivery and the stability considerations concerning long-term storage. MDPI 2021-12-27 /pmc/articles/PMC8773365/ /pubmed/35052730 http://dx.doi.org/10.3390/biomedicines10010050 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ouranidis, Andreas
Vavilis, Theofanis
Mandala, Evdokia
Davidopoulou, Christina
Stamoula, Eleni
Markopoulou, Catherine K.
Karagianni, Anna
Kachrimanis, Kyriakos
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
title mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
title_full mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
title_fullStr mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
title_full_unstemmed mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
title_short mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
title_sort mrna therapeutic modalities design, formulation and manufacturing under pharma 4.0 principles
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773365/
https://www.ncbi.nlm.nih.gov/pubmed/35052730
http://dx.doi.org/10.3390/biomedicines10010050
work_keys_str_mv AT ouranidisandreas mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT vavilistheofanis mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT mandalaevdokia mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT davidopoulouchristina mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT stamoulaeleni mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT markopouloucatherinek mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT karagiannianna mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles
AT kachrimaniskyriakos mrnatherapeuticmodalitiesdesignformulationandmanufacturingunderpharma40principles